Matos Garcia, I., García Ruiz, A., Martin-Liberal, J., Hierro, C., Ochoa De Olza Amat, M., Viaplana, C., Mur, G., Vieito Villar, M., Brana, I., Azaro, A., Perez, C., Rodriguez Freixinos, V., Argiles, G., Oliveira, M., Felip Font, E., Muñoz-Couselo, E., Tabernero, J., Dienstmann, R., & Garralda, E. (n.d.). 1841PRefining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability. Annals of oncology, 29, . http://access.bl.uk/ark:/81055/vdc_100095477370.0x000034